Recent Developments of 19-Nor-1,25-dihydroxyvitamin D3 Analogues

The vitamin D hormone, 1α,25‐dihydroxyvitamin D3 [1,25‐(OH)2D3], exerts its hormonal effects predominantly on intestine, bone, and kidney, where it plays a crucial role in calcium and phosphorus homeostasis and bone mineralization. In addition to its classical actions, 1,25(OH)2D3 exerts pleiotropic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ChemMedChem 2013-08, Vol.8 (8), p.1249-1260
Hauptverfasser: Zhang, Can-Fei, Wan, Ren-Zhong, Liu, Zhao-Peng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1260
container_issue 8
container_start_page 1249
container_title ChemMedChem
container_volume 8
creator Zhang, Can-Fei
Wan, Ren-Zhong
Liu, Zhao-Peng
description The vitamin D hormone, 1α,25‐dihydroxyvitamin D3 [1,25‐(OH)2D3], exerts its hormonal effects predominantly on intestine, bone, and kidney, where it plays a crucial role in calcium and phosphorus homeostasis and bone mineralization. In addition to its classical actions, 1,25(OH)2D3 exerts pleiotropic effects in a wide variety of target tissues and cell types, often in an autocrine/paracrine fashion. These biological activities of 1,25(OH)2D3 have suggested a multitude of potential therapeutic applications for the vitamin D hormone in the treatment of hyperproliferative disorders (e.g. cancer and psoriasis), immune dysfunction (autoimmune diseases), and endocrine disorders (e.g. hyperparathyroidism). However, the calcemic effects induced by 1,25(OH)2D3—hypercalcemia, increased bone resorption, and soft tissue calcification—limit the use of the natural ligand in these clinical applications. Therefore, numerous 1,25(OH)2D3 analogues have been synthesized with the intent of producing therapeutic agents devoid of hypercalcemic and hyperphosphatemic side effects. To this aim, much attention has been focused on the development of 19‐nor‐vitamin D3 derivatives that lack the ring‐A exocyclic methylene group (C19). In this review, the 19‐nor‐1,25(OH)2D3 analogues are classified according to modifications made at the A‐ring, the side chain, or both the A‐ring and side chain, as well as other positions. The biological activities of these 19‐nor‐1,25(OH)2D3 analogues are summarized and their structure–activity relationships and binding features with the vitamin D receptor (VDR) are discussed. Vital analogues: The use of 1,25(OH)2D3 for the treatment of a wide variety of diseases was limited by the parallel induction of hypercalcemic effects. There is an urgent need to find novel agents with greater selectivity. This review highlights recent advances in the research of 19‐nor‐1,25‐dihydroxyvitamin D3 analogues, paying special attention to their activities and structure– activity relationships.
doi_str_mv 10.1002/cmdc.201300160
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1415609866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1415609866</sourcerecordid><originalsourceid>FETCH-LOGICAL-i1440-6e7cdd2f2c0a756d0cfab7b26e9ce8714df6e3992f16010f8e7a2ece3ee291993</originalsourceid><addsrcrecordid>eNo9ULtOw0AQPCEQCYGWErmk4MI9fK8yOBCQQkAQRHm62Gsw2HGwnRB3NPwoX4JRgqud1c7s7gxCx5T0KSHsPMyisM8I5YRQSXZQl2pJsKJa7bZYmQ46KMs3QnxfU72POowrrYXwu-jiAUKYV94QVpDmi6zBpZfHHjV4kheYnjGBo-S1jop8Xa-SymXJ_Ofre8i9wdyl-csSykO0F7u0hKNt7aGnq8tpcI3Hd6ObYDDGCfV9giWoMIpYzELilJARCWM3UzMmwYSgFfWjWAI3hsWNEUpiDcqx5jkOwAw1hvfQ6Wbvosg_mruVzZIyhDR1c8iXpaU-FZIYLWVDPdlSl7MMIrsokswVtf333RDMhvCZpFC3c0rsX6r2L1XbpmqD22HQdo0Wb7RJWcG61bri3UrFlbDPk5EVjyy4N1NpBf8F0eJ5mA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1415609866</pqid></control><display><type>article</type><title>Recent Developments of 19-Nor-1,25-dihydroxyvitamin D3 Analogues</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Zhang, Can-Fei ; Wan, Ren-Zhong ; Liu, Zhao-Peng</creator><creatorcontrib>Zhang, Can-Fei ; Wan, Ren-Zhong ; Liu, Zhao-Peng</creatorcontrib><description>The vitamin D hormone, 1α,25‐dihydroxyvitamin D3 [1,25‐(OH)2D3], exerts its hormonal effects predominantly on intestine, bone, and kidney, where it plays a crucial role in calcium and phosphorus homeostasis and bone mineralization. In addition to its classical actions, 1,25(OH)2D3 exerts pleiotropic effects in a wide variety of target tissues and cell types, often in an autocrine/paracrine fashion. These biological activities of 1,25(OH)2D3 have suggested a multitude of potential therapeutic applications for the vitamin D hormone in the treatment of hyperproliferative disorders (e.g. cancer and psoriasis), immune dysfunction (autoimmune diseases), and endocrine disorders (e.g. hyperparathyroidism). However, the calcemic effects induced by 1,25(OH)2D3—hypercalcemia, increased bone resorption, and soft tissue calcification—limit the use of the natural ligand in these clinical applications. Therefore, numerous 1,25(OH)2D3 analogues have been synthesized with the intent of producing therapeutic agents devoid of hypercalcemic and hyperphosphatemic side effects. To this aim, much attention has been focused on the development of 19‐nor‐vitamin D3 derivatives that lack the ring‐A exocyclic methylene group (C19). In this review, the 19‐nor‐1,25(OH)2D3 analogues are classified according to modifications made at the A‐ring, the side chain, or both the A‐ring and side chain, as well as other positions. The biological activities of these 19‐nor‐1,25(OH)2D3 analogues are summarized and their structure–activity relationships and binding features with the vitamin D receptor (VDR) are discussed. Vital analogues: The use of 1,25(OH)2D3 for the treatment of a wide variety of diseases was limited by the parallel induction of hypercalcemic effects. There is an urgent need to find novel agents with greater selectivity. This review highlights recent advances in the research of 19‐nor‐1,25‐dihydroxyvitamin D3 analogues, paying special attention to their activities and structure– activity relationships.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.201300160</identifier><identifier>PMID: 23788554</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>1,25(OH)2D3 ; 19-nor-1 ; 19‐nor‐1,25(OH)2D3 ; 25(OH)2D3 ; Calcitriol - analogs &amp; derivatives ; Calcitriol - chemistry ; Calcitriol - metabolism ; Calcitriol - pharmacology ; Cell Differentiation - drug effects ; Humans ; Protein Binding ; Receptors, Calcitriol - metabolism ; steroids ; Structure-Activity Relationship ; structure-activity relationships ; VDR</subject><ispartof>ChemMedChem, 2013-08, Vol.8 (8), p.1249-1260</ispartof><rights>Copyright © 2013 WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><rights>Copyright © 2013 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcmdc.201300160$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcmdc.201300160$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23788554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Can-Fei</creatorcontrib><creatorcontrib>Wan, Ren-Zhong</creatorcontrib><creatorcontrib>Liu, Zhao-Peng</creatorcontrib><title>Recent Developments of 19-Nor-1,25-dihydroxyvitamin D3 Analogues</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>The vitamin D hormone, 1α,25‐dihydroxyvitamin D3 [1,25‐(OH)2D3], exerts its hormonal effects predominantly on intestine, bone, and kidney, where it plays a crucial role in calcium and phosphorus homeostasis and bone mineralization. In addition to its classical actions, 1,25(OH)2D3 exerts pleiotropic effects in a wide variety of target tissues and cell types, often in an autocrine/paracrine fashion. These biological activities of 1,25(OH)2D3 have suggested a multitude of potential therapeutic applications for the vitamin D hormone in the treatment of hyperproliferative disorders (e.g. cancer and psoriasis), immune dysfunction (autoimmune diseases), and endocrine disorders (e.g. hyperparathyroidism). However, the calcemic effects induced by 1,25(OH)2D3—hypercalcemia, increased bone resorption, and soft tissue calcification—limit the use of the natural ligand in these clinical applications. Therefore, numerous 1,25(OH)2D3 analogues have been synthesized with the intent of producing therapeutic agents devoid of hypercalcemic and hyperphosphatemic side effects. To this aim, much attention has been focused on the development of 19‐nor‐vitamin D3 derivatives that lack the ring‐A exocyclic methylene group (C19). In this review, the 19‐nor‐1,25(OH)2D3 analogues are classified according to modifications made at the A‐ring, the side chain, or both the A‐ring and side chain, as well as other positions. The biological activities of these 19‐nor‐1,25(OH)2D3 analogues are summarized and their structure–activity relationships and binding features with the vitamin D receptor (VDR) are discussed. Vital analogues: The use of 1,25(OH)2D3 for the treatment of a wide variety of diseases was limited by the parallel induction of hypercalcemic effects. There is an urgent need to find novel agents with greater selectivity. This review highlights recent advances in the research of 19‐nor‐1,25‐dihydroxyvitamin D3 analogues, paying special attention to their activities and structure– activity relationships.</description><subject>1,25(OH)2D3</subject><subject>19-nor-1</subject><subject>19‐nor‐1,25(OH)2D3</subject><subject>25(OH)2D3</subject><subject>Calcitriol - analogs &amp; derivatives</subject><subject>Calcitriol - chemistry</subject><subject>Calcitriol - metabolism</subject><subject>Calcitriol - pharmacology</subject><subject>Cell Differentiation - drug effects</subject><subject>Humans</subject><subject>Protein Binding</subject><subject>Receptors, Calcitriol - metabolism</subject><subject>steroids</subject><subject>Structure-Activity Relationship</subject><subject>structure-activity relationships</subject><subject>VDR</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9ULtOw0AQPCEQCYGWErmk4MI9fK8yOBCQQkAQRHm62Gsw2HGwnRB3NPwoX4JRgqud1c7s7gxCx5T0KSHsPMyisM8I5YRQSXZQl2pJsKJa7bZYmQ46KMs3QnxfU72POowrrYXwu-jiAUKYV94QVpDmi6zBpZfHHjV4kheYnjGBo-S1jop8Xa-SymXJ_Ofre8i9wdyl-csSykO0F7u0hKNt7aGnq8tpcI3Hd6ObYDDGCfV9giWoMIpYzELilJARCWM3UzMmwYSgFfWjWAI3hsWNEUpiDcqx5jkOwAw1hvfQ6Wbvosg_mruVzZIyhDR1c8iXpaU-FZIYLWVDPdlSl7MMIrsokswVtf333RDMhvCZpFC3c0rsX6r2L1XbpmqD22HQdo0Wb7RJWcG61bri3UrFlbDPk5EVjyy4N1NpBf8F0eJ5mA</recordid><startdate>201308</startdate><enddate>201308</enddate><creator>Zhang, Can-Fei</creator><creator>Wan, Ren-Zhong</creator><creator>Liu, Zhao-Peng</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201308</creationdate><title>Recent Developments of 19-Nor-1,25-dihydroxyvitamin D3 Analogues</title><author>Zhang, Can-Fei ; Wan, Ren-Zhong ; Liu, Zhao-Peng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i1440-6e7cdd2f2c0a756d0cfab7b26e9ce8714df6e3992f16010f8e7a2ece3ee291993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>1,25(OH)2D3</topic><topic>19-nor-1</topic><topic>19‐nor‐1,25(OH)2D3</topic><topic>25(OH)2D3</topic><topic>Calcitriol - analogs &amp; derivatives</topic><topic>Calcitriol - chemistry</topic><topic>Calcitriol - metabolism</topic><topic>Calcitriol - pharmacology</topic><topic>Cell Differentiation - drug effects</topic><topic>Humans</topic><topic>Protein Binding</topic><topic>Receptors, Calcitriol - metabolism</topic><topic>steroids</topic><topic>Structure-Activity Relationship</topic><topic>structure-activity relationships</topic><topic>VDR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Can-Fei</creatorcontrib><creatorcontrib>Wan, Ren-Zhong</creatorcontrib><creatorcontrib>Liu, Zhao-Peng</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Can-Fei</au><au>Wan, Ren-Zhong</au><au>Liu, Zhao-Peng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent Developments of 19-Nor-1,25-dihydroxyvitamin D3 Analogues</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2013-08</date><risdate>2013</risdate><volume>8</volume><issue>8</issue><spage>1249</spage><epage>1260</epage><pages>1249-1260</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>The vitamin D hormone, 1α,25‐dihydroxyvitamin D3 [1,25‐(OH)2D3], exerts its hormonal effects predominantly on intestine, bone, and kidney, where it plays a crucial role in calcium and phosphorus homeostasis and bone mineralization. In addition to its classical actions, 1,25(OH)2D3 exerts pleiotropic effects in a wide variety of target tissues and cell types, often in an autocrine/paracrine fashion. These biological activities of 1,25(OH)2D3 have suggested a multitude of potential therapeutic applications for the vitamin D hormone in the treatment of hyperproliferative disorders (e.g. cancer and psoriasis), immune dysfunction (autoimmune diseases), and endocrine disorders (e.g. hyperparathyroidism). However, the calcemic effects induced by 1,25(OH)2D3—hypercalcemia, increased bone resorption, and soft tissue calcification—limit the use of the natural ligand in these clinical applications. Therefore, numerous 1,25(OH)2D3 analogues have been synthesized with the intent of producing therapeutic agents devoid of hypercalcemic and hyperphosphatemic side effects. To this aim, much attention has been focused on the development of 19‐nor‐vitamin D3 derivatives that lack the ring‐A exocyclic methylene group (C19). In this review, the 19‐nor‐1,25(OH)2D3 analogues are classified according to modifications made at the A‐ring, the side chain, or both the A‐ring and side chain, as well as other positions. The biological activities of these 19‐nor‐1,25(OH)2D3 analogues are summarized and their structure–activity relationships and binding features with the vitamin D receptor (VDR) are discussed. Vital analogues: The use of 1,25(OH)2D3 for the treatment of a wide variety of diseases was limited by the parallel induction of hypercalcemic effects. There is an urgent need to find novel agents with greater selectivity. This review highlights recent advances in the research of 19‐nor‐1,25‐dihydroxyvitamin D3 analogues, paying special attention to their activities and structure– activity relationships.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>23788554</pmid><doi>10.1002/cmdc.201300160</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1860-7179
ispartof ChemMedChem, 2013-08, Vol.8 (8), p.1249-1260
issn 1860-7179
1860-7187
language eng
recordid cdi_proquest_miscellaneous_1415609866
source MEDLINE; Access via Wiley Online Library
subjects 1,25(OH)2D3
19-nor-1
19‐nor‐1,25(OH)2D3
25(OH)2D3
Calcitriol - analogs & derivatives
Calcitriol - chemistry
Calcitriol - metabolism
Calcitriol - pharmacology
Cell Differentiation - drug effects
Humans
Protein Binding
Receptors, Calcitriol - metabolism
steroids
Structure-Activity Relationship
structure-activity relationships
VDR
title Recent Developments of 19-Nor-1,25-dihydroxyvitamin D3 Analogues
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T23%3A18%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20Developments%20of%2019-Nor-1,25-dihydroxyvitamin%E2%80%85D3%20Analogues&rft.jtitle=ChemMedChem&rft.au=Zhang,%20Can-Fei&rft.date=2013-08&rft.volume=8&rft.issue=8&rft.spage=1249&rft.epage=1260&rft.pages=1249-1260&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.201300160&rft_dat=%3Cproquest_pubme%3E1415609866%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1415609866&rft_id=info:pmid/23788554&rfr_iscdi=true